Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
07:00am, Tuesday, 12'th May 2026
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C.
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
07:00am, Tuesday, 05'th May 2026
Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in the coming weeks Seres maintains operational focus on advancing live biother
Data highlight both SER-603's rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomar
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
07:00am, Monday, 20'th Apr 2026
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
Seres Therapeutics to Present at CARB-X Investor Day
07:00am, Thursday, 09'th Apr 2026
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at th
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 12'th Mar 2026
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
04:05pm, Monday, 02'nd Mar 2026
Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
08:29am, Thursday, 12'th Feb 2026
Seres Therapeutics Inc. (NASDAQ: MCRB) shares are down during Thursday's premarket session following the company's announcement of a strategic shift in its operations.
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
07:00am, Thursday, 12'th Feb 2026
Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup activ
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving Average – Time to Sell?
04:20am, Wednesday, 11'th Feb 2026
Shares of Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $15.49 and traded as low
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average – Time to Sell?
04:52am, Friday, 16'th Jan 2026
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report) crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $16.63 and traded as low as
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
11:15am, Monday, 29'th Dec 2025
Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened
04:14am, Friday, 05'th Dec 2025
Seres Therapeutics, Inc. (NASDAQ: MCRB - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $18.13 and traded a
